Cystine-knot peptides: Emerging tools for cancer imaging and therapy

Expert Review of Proteomics

Volumn 11, Issue 5, 2014, Pages 561-572

  Ackerman, Shelley E ^a   Currier, Nicolas V ^b   Bergen, Jamie M ^a   Cochran, Jennifer R ^a  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

disulfide rich peptides; drug discovery; knottin; miniprotein; molecular imaging; protein engineering; therapeutics; tumor targeting

Indexed keywords

KNOTTIN; ANTINEOPLASTIC AGENT; CYCLOTIDE; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

AMINO ACID SEQUENCE; CANCER DIAGNOSIS; CANCER IMAGING; CANCER THERAPY; CHRONIC PAIN; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; HUMAN; IRRITABLE COLON; MOLECULAR IMAGING; NONHUMAN; PROTEIN ENGINEERING; REVIEW; ANIMAL; IRRITABLE BOWEL SYNDROME; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CHRONIC PAIN; CYCLOTIDES; CYSTINE-KNOT MINIPROTEINS; HUMANS; IRRITABLE BOWEL SYNDROME; MOLECULAR IMAGING; NEOPLASMS; PROTEIN ENGINEERING; RADIOPHARMACEUTICALS;

EID: 84907271376     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.932251     Document Type: Review

References (104)

1. Kolmar H. Natural and engineered cystine knot miniproteins for diagnostic and therapeutic applications. Curr Pharm Des 2011;17(38):4329-36
2. Moore SJ, Leung CL, Cochran JR. Knottins: disulfide-bonded therapeutic and diagnostic peptides. Drug Discov Today Technol 2012;9(1):e3-11
3. Daly NL, Craik DJ. Bioactive cystine knot proteins. Curr Opin Chem Biol 2011;15(3): 362-8
4. Le Nguyen D, Heitz A, Chiche L, et al. Molecular recognition between serine proteases and new bioactive microproteins with a knotted structure. Biochimie 1990; 72(6-7):431-5
5. Colgrave ML, Craik DJ. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 2004;43(20): 5965-75
6. Werle M, Schmitz T, Huang HL, et al. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J Drug Target 2006; 14(3):137-46
7. Gracy J, Le-Nguyen D, Gelly JC, et al. KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007. Nucleic Acids Res 2008;36(Database issue):D314-19
8. The KNOTTIN database. Knottins are intriguing miniproteins with strong potential in drug design. Available from: http://knottin.cbs.cnrs.fr
9. Zhu S, Darbon H, Dyason K, et al. Evolutionary origin of inhibitor cystine knot peptides. FASEB J 2003;17(12):1765-7
10. Pallaghy PK, Nielsen KJ, Craik DJ, Norton RS. A common structural motif incorporating a cystine knot and a triple-stranded beta-sheet in toxic and inhibitory polypeptides. Protein Sci 1994; 3(10):1833-9
11. Craik DJ, Daly NL, Bond T, Waine C. Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol 1999;294(5):1327-36
12. Wang CK, Kaas Q, Chiche L, Craik DJ. CyBase: A database of cyclic protein sequences and structures, with applications in protein discovery and engineering. Nucleic Acids Res 2008;36(Database issue): D206-10
13. The database of cyclic proteins. Available from: http://cybase.org.au
14. Kolmar H. Engineered cystine-knot miniproteins for diagnostic applications. Expert Rev Mol Diagn 2010;10(3):361-8
15. Gould A, Ji Y, Aboye TL, Camarero JA. Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. Curr Pharm Des 2011;17(38):4294-307
16. Maillere B, Mourier G, Herve M, et al. Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step. Toxicon 1995;33(4): 475-82
17. Jiang L, Miao Z, Kimura RH, et al. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis. J Biomed Biotechnol 2012;2012:368075
18. Clark RJ, Craik DJ. Engineering cyclic peptide toxins. Methods Enzymol 2012;503: 57-74
19. Klint JK, Senff S, Saez NJ, et al. Production of recombinant disulfide-rich venom peptides for structural and functional analysis via expression in the periplasm of E. coli. PLoS One 2013;8(5):e63865
20. Moore SJ, Cochran JR. Engineering knottins as novel binding agents. Methods Enzymol 2012;503:223-51
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74
22. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012;6(2):155-76
23. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349(15):1451-64
24. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76(9):1704-9
25. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 1990;50(14):4177-89
26. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 2010;87(5):543-52
27. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010;9(10):767-74
28. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93(11):2645-68
29. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12(4):278-87
30. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23(9):1105-16
31. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007;67(1):254-61
32. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 2007;13(24): 7264-70
33. Condeelis J, Weissleder R. In vivo imaging in cancer. Cold Spring Harb Perspect Biol 2010;2(12):a003848
34. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol 2008;26(24): 4012-21
35. Fass L. Imaging and cancer: A review. Mol Oncol 2008;2(2):115-52
36. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 2012;92(2): 897-965
37. Friedman M, Stahl S. Engineered affinity proteins for tumour-targeting applications. Biotechnol Appl Biochem 2009;53(Pt 1): 1-29
38. Stern LA, Case BA, Hackel BJ. Alternative non-Antibody protein scaffolds for molecular imaging of cancer. Curr Opin Chem Eng 2013;2(4):425-32
39. Chen K, Chen X. Design and development of molecular imaging probes. Curr Top Med Chem 2010;10(12):1227-36
40. Reynolds F, Kelly KA. Techniques for molecular imaging probe design. Mol Imaging 2011;10(6):407-19
41. Bouvet M, Hoffman RM. Glowing tumors make for better detection and resection. Sci Transl Med 2011;3(110):110fs110
42. Craik DJ, Cemazar M, Wang CK, Daly NL. The cyclotide family of circular miniproteins: Nature's combinatorial peptide template. Biopolymers 2006;84(3):250-66
43. Sollod BL, Wilson D, Zhaxybayeva O, et al Were arachnids the first to use combinatorial peptide libraries? Peptides 2005;26(1):131-9
44. Miljanich GP. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004;11(23): 3029-40
45. Christmann A, Walter K, Wentzel A, et al. The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides. Protein Eng 1999;12(9):797-806
46. Getz JA, Cheneval O, Craik DJ, Daugherty PS. Design of a cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration. ACS Chem Biol 2013;8(6):1147-54
47. Silverman AP, Levin AM, Lahti JL, Cochran JR. Engineered cystine-knot peptides that bind alphav beta3 integrin with antibody-like affinities. J Mol Biol 2009;385(4):1064-75
48. Heitz A, Avrutina O, Le-Nguyen D, et al. Knottin cyclization: impact on structure and dynamics. BMC Struct Biol 2008;8:54
49. Heitz A, Hernandez JF, Gagnon J, et al. Solution structure of the squash trypsin inhibitor MCoTI-II. A new family for cyclic knottins. Biochemistry 2001;40(27):7973-83
50. Eliasen R, Daly NL, Wulff BS, et al. Design, synthesis, structural and functional characterization of novel melanocortin agonists based on the cyclotide kalata B1. J Biol Chem 2012;287(48):40493-501
51. Jackson PJ, McNulty JC, Yang YK, et al. Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity. Biochemistry 2002;41(24):7565-72
52. Jiang L, Kimura RH, Miao Z, et al. Evaluation of a 64Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med 2010; 51(2):251-8
53. Miao Z, Ren G, Liu H, et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 2009;20(12):2342-7
54. Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998;58(21):4871-9
55. Lippens G, Najib J, Wodak SJ, Tartar A. NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry 1995;34(1):13-21
56. Veiseh M, Gabikian P, Bahrami SB, et al. Tumor paint: A chlorotoxin: cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007;67(14):6882-8
57. Kesavan K, Ratliff J, Johnson EW, et al. Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-Angiogenic effects. J Biol Chem 2010; 285(7):4366-74
58. Akcan M, Stroud MR, Hansen SJ, et al. Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy. J Med Chem 2011;54(3):782-7
59. Butte PV, Mamelak A, Parrish-Novak J, et al. Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors. Neurosurg Focus 2014;36(2):E1
60. Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv 2007; 4(2):175-86
61. Stroud MR, Hansen SJ, Olson JM. In vivo bio-imaging using chlorotoxin-based conjugates. Curr Pharm Des 2011;17(38): 4362-71
62. Mamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-Administered iodine-131-TM- 601 in adults with recurrent high-grade glioma. J Clin Oncol 2006;24(22):3644-50
63. Moore SJ, Leung CL, Norton HK, Cochran JR. Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. PLoS ONE 2013;8(4):e60498
64. Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 2009; 77(2):359-69
65. Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: A new class of agents for imaging integrin expression in living subjects. Cancer Res 2009;69(6):2435-42
66. Nielsen CH, Kimura RH, Withofs N, et al. PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res 2010;70(22):9022-30
67. Jiang L, Miao Z, Kimura RH, et al. Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 2010;38(4):613-22
68. Moore SJ, Hayden Gephart MG, Bergen JM, et al. Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma. Proc Natl Acad Sci USA 2013;110(36):14598-603
69. Silverman AP, Kariolis MS, Cochran JR. Cystine-knot peptides engineered with specificities for alpha(IIb)beta(3) or alpha (IIb)beta(3) and alpha(v)beta(3) integrins are potent inhibitors of platelet aggregation. J Mol Recognit 2011;24(1):127-35
70. Kimura RH, Teed R, Hackel BJ, et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res 2012;18(3):839-49
71. Hackel BJ, Kimura RH, Miao Z, et al. 18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin alphavbeta6. J Nucl Med 2013;54(7): 1101-5
72. Zhu X, Li J, Hong Y, et al. 99mTc-labeled cystine knot peptide targeting integrin alphavbeta6 for tumor SPECT imaging. Mol Pharm 2014;11(4):1208-17
73. Gunasekera S, Foley FM, Clark RJ, et al. Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides. J Med Chem 2008;51(24):7697-704
74. Thongyoo P, Bonomelli C, Leatherbarrow RJ, Tate EW. Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. J Med Chem 2009;52(20): 6197-200
75. Glotzbach B, Reinwarth M, Weber N, et al. Combinatorial optimization of cystine-knot peptides towards high-Affinity inhibitors of human matriptase-1. PLoS ONE 2013; 8(10):e76956
76. Greenwood KP, Daly NL, Brown DL, et al. The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis. Int J Biochem Cell Biol 2007;39(12):2252-64
77. Ji Y, Majumder S, Millard M, et al. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J Am Chem Soc 2013;135(31):11623-33
78. Aboye TL, Ha H, Majumder S, et al. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem 2012;55(23):10729-34
79. DeMarco SJ, Henze H, Lederer A, et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg Med Chem 2006;14(24):8396-404
80. Popp MW, Dougan SK, Chuang TY, et al. Sortase-catalyzed transformations that improve the properties of cytokines. Proc Natl Acad Sci USA 2011;108(8):3169-74
81. Getz JA, Rice JJ, Daugherty PS. Protease-resistant peptide ligands from a knottin scaffold library. ACS Chem Biol 2011;6(8):837-44
82. Wong CT, Rowlands DK, Wong CH, et al. Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew Chem Int Ed Engl 2012; 51(23):5620-4
83. Clark RJ, Jensen J, Nevin ST, et al. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew Chem Int Ed Engl 2010;49(37):6545-8
84. Layer P, Stanghellini V. Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2014;39(4):371-84
85. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365(6):527-36
86. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13(3):245-55
87. Banta S, Dooley K, Shur O. Replacing antibodies: engineering new binding proteins. Annu Rev Biomed Eng 2013;15: 93-113
88. Lee CH, Park KJ, Sung ES, et al. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc Natl Acad Sci USA 2010;107(21): 9567-71
89. Swedberg JE, de Veer SJ, Harris JM. Natural and engineered kallikrein inhibitors: An emerging pharmacopoeia. Biol Chem 2010;391(4):357-74
90. Silverman J, Liu Q, Bakker A, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005;23(12): 1556-61
91. Weidle UH, Auer J, Brinkmann U, et al. The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics 2013; 10(4):155-68
92. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006;66(8):4339-48
93. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8(10):2861-71
94. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-Affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70(4):1595-605
95. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012;503:255-68
96. Krause S, Schmoldt HU, Wentzel A, et al. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-Affinity thrombopoietin antagonists and agonists. FEBS J 2007; 274(1):86-95
97. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22(6):868-76
98. Willmann JK, Kimura RH, Deshpande N, et al. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010;51(3): 433-40
99. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5(10):796-806
100. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013; 81(1):113-21
101. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91
102. Younes A, Bartlett NL, Leonard JP, et al Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812-21
103. Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother 2013;62(2):217-23
104. Kryshtafovych A, Moult J, Bales P, et al. Challenging the state of the art in protein structure prediction: highlights of experimental target structures for the 10th Critical Assessment of Techniques for Protein Structure Prediction Experiment CASP10. Proteins 2014;82(Suppl 2):26-42.